Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:GBT Global Blood Therapeutics (GBT) Stock Price, News & Analysis Add Share Share Stock Analysis Stock Analysis About Global Blood Therapeutics Stock (NASDAQ:GBT) 30 days 90 days 365 days Advanced Chart Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get GBT alerts:Sign Up Key Stats Today's Range$68.49▼$68.4950-Day Range$68.07▼$68.4952-Week Range$21.65▼$73.02Volume74 shsAverage Volume2.07 million shsMarket Capitalization$4.62 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewGlobal Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.Read More… Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Receive GBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GBT Stock News HeadlinesLouisville men's basketball coach Pat Kelsey on 3-point shooting, bench depth and 'GBT'October 25, 2024 | sports.yahoo.comActivist investor Starboard forges $1bn stake in Pfizer to swing profitsOctober 7, 2024 | msn.com2024 Election Year Stocks: Uncover Hidden Gems!In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.November 21, 2024 | Darwin (Ad)Activist investor Starboard Value takes $1 billion stake in Pfizer, sources sayOctober 7, 2024 | finance.yahoo.comActivist investor Starboard Value takes $1 bln stake in Pfizer, sources sayOctober 7, 2024 | reuters.comPfizer: Growth From Oncology Franchise; Initiate With 'Buy'October 1, 2024 | seekingalpha.comPfizer Sickle Cell Treatment Suspended by Europe in New SetbackSeptember 27, 2024 | finance.yahoo.comPfizer to pull sickle cell drug from market, shut down trialsSeptember 26, 2024 | finance.yahoo.comSee More Headlines GBT Stock Analysis - Frequently Asked Questions How were Global Blood Therapeutics' earnings last quarter? Global Blood Therapeutics, Inc. (NASDAQ:GBT) announced its quarterly earnings results on Thursday, November, 4th. The company reported ($1.13) EPS for the quarter, missing analysts' consensus estimates of ($1.10) by $0.03. The firm's quarterly revenue was up 41.1% on a year-over-year basis. When did Global Blood Therapeutics IPO? Global Blood Therapeutics (GBT) raised $102 million in an initial public offering (IPO) on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers. What other stocks do shareholders of Global Blood Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Global Blood Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Meta Platforms (META), Intel (INTC), Bristol-Myers Squibb (BMY) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/04/2021Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:GBT CUSIPN/A CIK1629137 Webwww.gbt.com Phone(650) 741-7700FaxN/AEmployees457Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-303,090,000.00 Net Margins-137.30% Pretax Margin-137.01% Return on Equity-170.37% Return on Assets-39.24% Debt Debt-to-Equity Ratio4.92 Current Ratio6.88 Quick Ratio6.17 Sales & Book Value Annual Sales$194.75 million Price / Sales23.73 Cash FlowN/A Price / Cash FlowN/A Book Value$3.05 per share Price / Book22.46Miscellaneous Outstanding Shares67,476,000Free Float64,170,000Market Cap$4.62 billion OptionableOptionable Beta0.45 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:GBT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global Blood Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Global Blood Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.